The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Conditions
- Advanced Solid TumorAdvanced Malignant NeoplasmMetastatic CancerMetastatic Solid TumorLung CancerOvarian CancerEndometrial CancerProstate CancerColorectal CancerBreast Cancer
- Interventions
- Registration Number
- NCT04585750
- Lead Sponsor
- PMV Pharmaceuticals, Inc
- Brief Summary
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab.
- Detailed Description
Rezatapopt is a first-in-class, oral, small molecule p53 reactivator that is selective for the TP53 Y220C mutation.
The primary objective of Phase 2 Monotherapy is to evaluate the efficacy of rezatapopt at the Recommended Phase 2 Dose (RP2D) including the Overall Response Rate (ORR) in the Ovarian Cancer Cohort and the ORR across all cohorts as determined by blinded independent central review. Secondary objectives of Phase 2 are to characterize the safety, pharmacokinetic (PK) properties, quality of life, and other efficacy measures of PC14586 rezatapopt at the RP2D. Enrollment is open for the Phase 2 Monotherapy portion of the study.
The primary objective of Phase 1 Monotherapy is to establish the maximum tolerated dose (MTD) and RP2D of rezatapopt. Secondary objectives are to characterize the PK properties, safety and tolerability, and to assess preliminary efficacy including ORR. Enrollment into Phase 1 Monotherapy is complete.
The primary objective of Phase 1b Combination Therapy is to establish the MTD/RP2D of rezatapopt when administered in combination with pembrolizumab. Secondary objectives of Phase 1b Combination Therapy are to characterize PK, safety and tolerability, and to assess preliminary efficacy of rezatapopt when administered in combination with pembrolizumab, including ORR. Enrollment into Phase 1b Combination Therapy is complete.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 230
- At least 18 years of age or 12 to 17 years of age after Safety Review Committee approval.
- Locally advanced or metastatic solid malignancy with a TP53 Y220C mutation
- Eastern Cooperative Oncology Group (ECOG) status of 0 or 1
- Previously treated with one or more lines of anticancer therapy and progressive disease
- Adequate organ function
- Measurable disease per RECIST v1.1 (Phase 2)
Additional Criteria for Inclusion in Phase 1b (rezatapopt) + pembrolizumab combination)
- Anti-PD-1/PD-L1 naive or must have progressed on treatment
- Measurable disease
- Anti-cancer therapy within 21 days (or 5 half-lives) of receiving the study drug
- Radiotherapy within 28 days of receiving the study drug
- Primary CNS tumor
- History of leptomeningeal disease or spinal cord compression
- Brain metastases, unless neurologically stable and do not require steroids to treat associated neurological symptoms
- Stroke or transient ischemic attack within 6 months prior to screening
- Heart conditions such as unstable angina, uncontrolled hypertension, a heart attack within 6 months prior to screening, congestive heart failure, prolongation of QT interval, or other rhythm abnormalities
- Strong CYP3A4 inducers
- History of gastrointestinal (GI) disease that may interfere with absorption of study drug or patients unable to take oral medication
- History of prior organ transplant
- Known, active malignancy, except for treated cervical intraepithelial neoplasia, or non-melanoma skin cancer
- Known, active uncontrolled Hepatitis B, Hepatitis C, or human immunodeficiency virus infection
Additional Criteria for Exclusion from Phase 2 (rezatapopt monotherapy)
- Known KRAS mutation, defined as a single nucleotide variant (SNV) (Phase 2)
Additional Criteria for Exclusion from Phase 1b (rezatapopt) + pembrolizumab combination)
- Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor and discontinued from that treatment due to a Grade 3 or higher immune-related AE (irAE)
- Received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention
- Diagnosis of immunodeficiency or receiving chronic systemic steroid therapy within 7 days prior to the first dose of study drug
- Hypersensitivity (≥ Grade 3) to pembrolizumab and/or any of its excipients
- Active autoimmune disease that has required systemic treatment in past 2 years
- History of radiation pneumonitis
- History of (non-infectious) or active pneumonitis / interstitial lung disease that required steroids
- Active infection requiring systemic therapy
- Known history of HIV infection
- Has previously received rezatapopt
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Phase 1 Monotherapy Dose Escalation rezatapopt Multiple dose levels of daily oral rezatapopt will be evaluated in an escalating manner, to determine the maximum tolerated dose and to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of rezatapopt to recommend a Phase 2 dose (RP2D). Phase 1b Combination Therapy Dose Escalation, Part 1 pembrolizumab Multiple dose levels of daily oral rezatapopt in combination with a stable dose of pembrolizumab (200 mg IV q3 weeks) will be evaluated in an escalating manner, to determine the maximum tolerated dose and to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of PC14586 to recommend a Phase 2 dose (RP2D) of rezatapopt when administered in combination with pembrolizumab. Phase 1b Combination Therapy Dose Expansion, PD(L)-1 naive patients pembrolizumab Additional (expansion of) participants will enroll at the RP2D of daily oral PC14586 (INN: rezatapopt) when administered in combination with pembrolizumab (200 mg IV q3 weeks) for continued evaluation. Participants will have advanced solid tumors harboring a p53 Y220C mutation and are PD(L)-1 naive patients. Phase 1b Combination Therapy Dose Expansion, PD(L)-1 relapsed/refractory patients pembrolizumab Additional (expansion of) participants will enroll at the RP2D of daily oral rezatapopt when administered in combination with pembrolizumab (200 mg IV q3 weeks) for continued evaluation. Participants will have advanced solid tumors harboring a p53 Y220C mutation and are PD(L)-1 relapsed/refractory patients. Phase 2 Monotherapy Dose Expansion, Ovarian Cancer Cohort rezatapopt Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Ovarian Cancer Cohort participants will have locally advanced or metastatic ovarian cancer harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1. Phase 1b Combination Therapy Dose Escalation, Part 1 rezatapopt Multiple dose levels of daily oral rezatapopt in combination with a stable dose of pembrolizumab (200 mg IV q3 weeks) will be evaluated in an escalating manner, to determine the maximum tolerated dose and to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of PC14586 to recommend a Phase 2 dose (RP2D) of rezatapopt when administered in combination with pembrolizumab. Phase 2 Monotherapy Dose Expansion, Lung Cancer Cohort rezatapopt Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Lung Cancer Cohort participants will have locally advanced or metastatic lung cancer harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1. Phase 1b Combination Therapy Dose Expansion, PD(L)-1 naive patients rezatapopt Additional (expansion of) participants will enroll at the RP2D of daily oral PC14586 (INN: rezatapopt) when administered in combination with pembrolizumab (200 mg IV q3 weeks) for continued evaluation. Participants will have advanced solid tumors harboring a p53 Y220C mutation and are PD(L)-1 naive patients. Phase 1b Combination Therapy Dose Expansion, PD(L)-1 relapsed/refractory patients rezatapopt Additional (expansion of) participants will enroll at the RP2D of daily oral rezatapopt when administered in combination with pembrolizumab (200 mg IV q3 weeks) for continued evaluation. Participants will have advanced solid tumors harboring a p53 Y220C mutation and are PD(L)-1 relapsed/refractory patients. Phase 2 Monotherapy Dose Expansion, Endometrial Cancer Cohort rezatapopt Additional (expansion of) participants will dose with 2000 mg daily oral rezatapopt with food for continued evaluation. Endometrial Cancer Cohort participants will have locally advanced or metastatic endometrial cancer harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1. Phase 2 Monotherapy Dose Expansion, Breast Cancer Cohort rezatapopt Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Breast Cancer Cohort participants will have locally advanced or metastatic breast cancer harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1. Phase 2 Monotherapy Dose Expansion, Other Solid Tumors Cohort rezatapopt Additional (expansion of) participants will dose with 2000 mg daily oral PC14586 (INN: rezatapopt) with food for continued evaluation. Other Solid Tumors Cohort participants will have locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation who meet all eligibility criteria and have measurable disease per RECIST 1.1.
- Primary Outcome Measures
Name Time Method Phase 1 Monotherapy (Dose Escalation): Determine the number and type of adverse events to characterize the safety of rezatapopt 40 months Number of participants with treatment related adverse events
Phase 1 Monotherapy (Dose Escalation): Establish the Recommended Phase 2 Dose (RP2D) 30 months RP2D will be determined using available safety and pharmacokinetics and pharmacodynamics data
Phase 1 Monotherapy (Dose Escalation): Establish the maximum tolerated dose (MTD) (Phase 1) The first 28 days of treatment (Cycle 1) per patient Incidence of dose limiting toxicities (DLTs) during the first 28 days of treatment with rezatapopt
Phase 1b Combination Therapy (Part 1: Dose Escalation): Determine the number and type of adverse events to characterize the safety of rezatapopt when administered in combination with pembrolizumab 18 months for treatment arm Number of participants with treatment related adverse events
Phase 1b Combination Therapy (Part 1: Dose Escalation): Establish the maximum tolerated dose (MTD) of rezatapopt when administered in combination with pembrolizumab The first 28 days of combination treatment arm (starting on Day -7) per patient Incidence of dose limiting toxicities (DLTs) during the first 28 days of treatment with rezatapopt
Phase 1b Combination Therapy (Part 1: Dose Escalation): Establish the Recommended Phase 2 Dose (RP2D) of rezatapopt when administered in combination with pembrolizumab 18 months RP2D will be determined using available safety and pharmacokinetics and pharmacodynamics data
Phase 1b Combination Therapy (Part 2: Dose Expansion): Determine the number and type of adverse events to characterize the safety of rezatapopt when administered in combination with pembrolizumab 12 months for treatment arm Number of participants with treatment related adverse events
Phase 2 Monotherapy (Dose Expansion): Response rate assessment to evaluate the clinical activity / efficacy of rezatapopt 34 months Overall response rate in accordance with Response Evaluation Criteria across all cohorts (RECIST) v.1.1 as assessed by independent review
- Secondary Outcome Measures
Name Time Method Phase 1 Monotherapy: PK profile of rezatapopt - Peak concentration (Cmax) Approximately 12 months per patient (75 months for Phase 1 and Phase 2) Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt
Phase 1 Monotherapy: PK profile of rezatapopt - Time of peak concentration (Tmax) Approximately 12 months per patient (75 months for Phase 1 and Phase 2) Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt
Phase 1 Monotherapy: PK profile of rezatapopt - Area under the plasma concentration-time curve from time zero to time of last sampling timepoint (AUC0-t) Approximately 12 months per patient (75 months for Phase 1 and Phase 2) Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt
Phase 1 Monotherapy: PK profile of rezatapopt - Area under the plasma concentration-time curve in one dosing interval (AUCtau) Approximately 12 months per patient (75 months for Phase 1 and Phase 2) Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt
Phase 1 Monotherapy: PK profile of rezatapopt - Trough observed concentrations (Ctrough/Ctau) Approximately 12 months per patient (75 months for Phase 1 and Phase 2) Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt
Phase 1 Monotherapy: Blood plasma assessment to describe the concentration of PC14586 and metabolite (M1) when rezatapopt is administered orally. Approximately 12 months per patient (75 months for Phase 1 and Phase 2) Blood plasma concentration
Phase 1 Monotherapy (Dose Escalation): Overall Response Rate per RECIST v1.1 or PCWG3 modified RECIST v1.1 41 months for study (end of Phase 1) Evaluation of preliminary anti-tumor activity of rezatapopt as a single agent
Phase 1 Monotherapy (Dose Escalation): Time to Response per RECIST v1.1 or PCWG3 modified RECIST v1.1 41 months for study (end of Phase 1) Evaluation of preliminary anti-tumor activity of rezatapopt as a single agent
Phase 1 Monotherapy (Dose Escalation): Duration of Response per RECIST v1.1 or PCWG3 modified RECIST v1.1 41 months for study (end of Phase 1) Evaluation of preliminary anti-tumor activity of rezatapopt as a single agent
Phase 1 Monotherapy (Dose Escalation): Disease Control Rate per RECIST v1.1 or PCWG3 modified RECIST v1.1 41 months for study (end of Phase 1) Evaluation of preliminary anti-tumor activity of rezatapopt as a single agent
Phase 1 Monotherapy (Dose Escalation): Progression Free Survival per RECIST v1.1 or PCWG3 modified RECIST v1.1 41 months for study (end of Phase 1) Evaluation of preliminary anti-tumor activity of rezatapopt as a single agent
Phase 1 Monotherapy (Dose Escalation): Overall Survival 41 months for study (end of Phase 1) Evaluation of preliminary anti-tumor activity of rezatapopt as a single agent
Phase 1b Combination Therapy: PK profile of rezatapopt in combination with pembrolizumab - Peak concentration (Cmax) Approximately 12 months per patient (30 months for treatment arm) Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt
Phase 1b Combination Therapy: PK profile of rezatapopt in combination with pembrolizumab - Time of peak concentration (Tmax) Approximately 12 months per patient (30 months for treatment arm) Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt
Phase 1b Combination Therapy: PK profile of rezatapopt in combination with pembrolizumab - Area under the plasma concentration-time curve from time zero to time of last sampling timepoint (AUC0-t) Approximately 12 months per patient (30 months for treatment arm) Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt
Phase 1b Combination Therapy: PK profile of rezatapopt in combination with pembrolizumab - Area under the plasma concentration-time curve in one dosing interval (AUCtau) Approximately 12 months per patient (30 months for treatment arm) Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt
Phase 1b Combination Therapy: PK profile of rezatapopt in combination with pembrolizumab - Trough observed concentrations (Ctrough/Ctau) Approximately 12 months per patient (30 months for treatment arm) Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt
Phase 1b Combination Therapy: Blood plasma assessment to describe the concentration of rezatapopt and metabolite (M1) when rezatapopt is administered orally in combination with pembrolizumab. Approximately 12 months per patient (30 months for treatment arm) Blood plasma concentration
Phase 1b Combination Therapy: Overall Response Rate per RECIST v1.1, iRECIST, or PCWG3 as assessed by Investigator and as assessed by independent review 30 months for study (end of Phase 1b) Evaluation of anti-tumor activity of rezatapopt in combination with pembrolizumab
Phase 1b Combination Therapy: Time to Response per RECIST v1.1, iRECIST, or PCWG3 as assessed by Investigator and as assessed by independent review 30 months for study (end of Phase 1b) Evaluation of anti-tumor activity of rezatapopt in combination with pembrolizumab
Phase 1b Combination Therapy: Duration of Response per RECIST v1.1, iRECIST, or PCWG3 as assessed by Investigator and as assessed by independent review 30 months for study (end of Phase 1b) Evaluation of anti-tumor activity of rezatapopt in combination with pembrolizumab
Phase 1b Combination Therapy: Disease Control Rate per RECIST v1.1, iRECIST, or PCWG3 as assessed by Investigator and as assessed by independent review 30 months for study (end of Phase 1b) Evaluation of anti-tumor activity of rezatapopt in combination with pembrolizumab
Phase 1b Combination Therapy: Overall Survival 30 months for study (end of Phase 1b) Evaluation of anti-tumor activity of rezatapopt in combination with pembrolizumab
Phase 1b Combination Therapy: Determine the number and type of adverse events to characterize the safety of rezatapopt 30 months for study (end of Phase 1b) Number of participants with treatment related adverse events
Phase 1b Combination Therapy: Progression Free Survival per RECIST v1.1, iRECIST, or PCWG3 as assessed by Investigator and as assessed by independent review 30 months for study (end of Phase 1b) Evaluation of anti-tumor activity of rezatapopt in combination with pembrolizumab
Phase 2 Monotherapy: PK profile of rezatapopt - Time of peak concentration (Tmax) Approximately 12 months per patient (75 months for Phase 1 and Phase 2) Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt
Phase 2 Monotherapy: PK profile of rezatapopt - Peak concentration (Cmax) Approximately 12 months per patient (75 months for Phase 1 and Phase 2) Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt
Phase 2 Monotherapy: PK profile of rezatapopt - Area under the plasma concentration-time curve from time zero to time of last sampling timepoint (AUC0-t) Approximately 12 months per patient (75 months for Phase 1 and Phase 2) Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt
Phase 2 Monotherapy: PK profile of rezatapopt - Area under the plasma concentration-time curve in one dosing interval (AUCtau) Approximately 12 months per patient (75 months for Phase 1 and Phase 2) Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt
Phase 2 Monotherapy: PK profile of rezatapopt - Trough observed concentrations (Ctrough/Ctau) Approximately 12 months per patient (75 months for Phase 1 and Phase 2) Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt
Phase 2 Monotherapy: Blood plasma assessment to describe the concentration of rezatapopt and metabolite (M1) when rezatapopt is administered orally. Approximately 12 months per patient (75 months for Phase 1 and Phase 2) Blood plasma concentration
Phase 2 Monotherapy (Dose Expansion): Determine the number and type of adverse events to characterize the safety of rezatapopt 34 months for study (end of Phase 2) Number of participants with treatment related adverse events
Phase 2 Monotherapy (Dose Expansion): Overall Response Rate across all cohorts per RECIST v1.1 as assessed by Investigator 34 months for study (end of Phase 2) Evaluation of anti-tumor activity of rezatapopt as a single agent
Phase 2 Monotherapy (Dose Expansion): Overall Response Rate in ovarian cancer cohort per RECIST v1.1 as assessed by Investigator 34 months for study (end of Phase 2) Evaluation of anti-tumor activity of rezatapopt as a single agent
Phase 2 Monotherapy (Dose Expansion): Time to Response in ovarian cancer cohort per RECIST v1.1 as assessed by Investigator and as assessed by independent review 34 months for study (end of Phase 2) Evaluation of anti-tumor activity of rezatapopt as a single agent
Phase 2 Monotherapy (Dose Expansion): Time to Response across all cohorts per RECIST v1.1 as assessed by Investigator and as assessed by independent review 34 months for study (end of Phase 2) Evaluation of anti-tumor activity of rezatapopt as a single agent
Phase 2 Monotherapy (Dose Expansion): Duration of Response in ovarian cancer cohort per RECIST v1.1 as assessed by Investigator and as assessed by independent review 34 months for study (end of Phase 2) Evaluation of anti-tumor activity of rezatapopt as a single agent
Phase 2 Monotherapy (Dose Expansion): Duration of Response across all cohorts per RECIST v1.1 as assessed by Investigator and as assessed by independent review 34 months for study (end of Phase 2) Evaluation of anti-tumor activity of rezatapopt as a single agent
Phase 2 Monotherapy (Dose Expansion): Disease Control Rate in ovarian cancer cohort per RECIST v1.1 as assessed by Investigator and as assessed by independent review 34 months for study (end of Phase 2) Evaluation of anti-tumor activity of rezatapopt as a single agent
Phase 2 Monotherapy (Dose Expansion): Disease Control Rate across all cohorts per RECIST v1.1 as assessed by Investigator and as assessed by independent review 34 months for study (end of Phase 2) Evaluation of anti-tumor activity of rezatapopt as a single agent
Phase 2 Monotherapy (Dose Expansion): Progression Free Survival in ovarian cancer cohort per RECIST v1.1 as assessed by Investigator and as assessed by independent review 34 months for study (end of Phase 2) Evaluation of anti-tumor activity of rezatapopt as a single agent
Phase 2 Monotherapy (Dose Expansion): Progression Free Survival across all cohorts per RECIST v1.1 as assessed by Investigator and as assessed by independent review 34 months for study (end of Phase 2) Evaluation of anti-tumor activity of rezatapopt as a single agent
Phase 2 Monotherapy (Dose Expansion): Overall Survival in ovarian cancer cohort 34 months for study (end of Phase 2) Evaluation of anti-tumor activity of rezatapopt as a single agent
Phase 2 Monotherapy (Dose Expansion): Overall Survival across all cohorts 34 months for study (end of Phase 2) Evaluation of anti-tumor activity of rezatapopt as a single agent
Phase 2 Monotherapy (Dose Expansion): Quality of life assessment Evaluated at every visit. 34 months for treatment arm (end of Phase 2) Changes from baseline in quality of life as measured by a validated instrument, for participants 18 and older
Trial Locations
- Locations (74)
Seoul University Hospital
🇰🇷Seoul, Korea, Republic of
Hoag Cancer Center
🇺🇸Irvine, California, United States
University of California Irvine Chao Family Comprehensive Cancer Center
🇺🇸Irvine, California, United States
UCLA Jonsson Comprehensive Cancer Center
🇺🇸Los Angeles, California, United States
USC Norris Comprehensive Cancer Center
🇺🇸Los Angeles, California, United States
University of San Francisco
🇺🇸San Francisco, California, United States
Rocky Mountain Cancer Center
🇺🇸Denver, Colorado, United States
Yale Cancer Center
🇺🇸New Haven, Connecticut, United States
Medical Oncology Hematology Consultants
🇺🇸Newark, Delaware, United States
University of Miami - Sylvester Comprehensive Cancer Center
🇺🇸Miami, Florida, United States
Florida Cancer Specialists South
🇺🇸Port Charlotte, Florida, United States
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
🇺🇸Chicago, Illinois, United States
Indiana University
🇺🇸Indianapolis, Indiana, United States
Massachusetts General Hospital
🇺🇸Boston, Massachusetts, United States
Dana Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
Karmanos Cancer Institute
🇺🇸Detroit, Michigan, United States
New York University
🇺🇸New York, New York, United States
Memorial Sloan Kettering
🇺🇸New York, New York, United States
Duke University
🇺🇸Durham, North Carolina, United States
The Cleveland Clinic Taussig Cancer Center
🇺🇸Cleveland, Ohio, United States
University of Oklahoma
🇺🇸Oklahoma City, Oklahoma, United States
Oregon Health & Science University (OHSU)
🇺🇸Portland, Oregon, United States
Abramson Cancer Center of the University of Pennsylvania
🇺🇸Philadelphia, Pennsylvania, United States
University of Pittsburgh Medical Center
🇺🇸Pittsburgh, Pennsylvania, United States
Medical University of South Carolina
🇺🇸Charleston, South Carolina, United States
Sarah Cannon Research Institute
🇺🇸Nashville, Tennessee, United States
Vanderbilt University Medical Center - Ingram Cancer Center
🇺🇸Nashville, Tennessee, United States
New Experimental Therapeutics - NEXT Oncology
🇺🇸Austin, Texas, United States
UT Southwest Simmons Cancer Center
🇺🇸Dallas, Texas, United States
The University of Texas MD Anderson Cancer Center
🇺🇸Houston, Texas, United States
New Experimental Therapeutics of San Antonio - NEXT Oncology
🇺🇸San Antonio, Texas, United States
Virginia Cancer Specialists
🇺🇸Fairfax, Virginia, United States
University of Washington, Fred Hutchinson Cancer Center
🇺🇸Seattle, Washington, United States
University of Wisconsin Carbone Cancer Center
🇺🇸Madison, Wisconsin, United States
Chris O'Brien Lifehouse Hospital
🇦🇺Camperdown, New South Wales, Australia
Mater Cancer Care Centre
🇦🇺South Brisbane, Queensland, Australia
Flinders Medical Center
🇦🇺Bedford Park, South Australia, Australia
Monash Medical Centre
🇦🇺Clayton, Victoria, Australia
Linear Clinical Research
🇦🇺Nedlands, Western Australia, Australia
ICANS - Institut de cancérologie Strasbourg Europe
🇫🇷Strasbourg, Bas-Rhin, France
Institut Bergonie
🇫🇷Bordeaux, Gironde, France
Institut Claudius Regaud
🇫🇷Toulouse, Haute-Garonne, France
EDOG Institut de Cancerologie de l'Ouest
🇫🇷Saint-Herblain, Loire-Atlantique, France
Centre Jean Perrin
🇫🇷Clermont-Ferrand, Puy-de-Dôme, France
Institut Gustave Roussy
🇫🇷Villejuif, Val-de-Marne, France
Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer
🇫🇷Lyon, France
CHU de Nîmes
🇫🇷Nîmes, France
Institute Cancer De Lorraine
🇫🇷Vandœuvre-lès-Nancy, France
Nationale Centrum für Tumorerkrankungen (NCT) Heidelberg
🇩🇪Heidelberg, Baden-Württemberg, Germany
Universitätsklinikum Augsburg
🇩🇪Augsburg, Bayern, Germany
Universitätsklinikum Frankfurt
🇩🇪Frankfurt, Hessen, Germany
Universitätsklinikum Essen
🇩🇪Essen, Nordrhein-Westfalen, Germany
Asklepios Klinik Altona
🇩🇪Hamburg, Germany
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
🇮🇹Rome, Lazio, Italy
Istituti Fisioterapici Ospitalieri - Istituto Nazionale Tumori Regina Elena
🇮🇹Rome, Lazio, Italy
ASST Grande Ospedale Metropolitano Niguarda
🇮🇹Milano, Lombardia, Italy
Fondazione IRCCS Istituto Nazionale Dei Tumori
🇮🇹Milano, Lombardia, Italy
Istituto Europeo Di Oncologia
🇮🇹Milano, Lombardia, Italy
Istituto Clinico Humanitas
🇮🇹Rozzano, Lombardia, Italy
Fondazione del Piemonte per l'Oncologia (IRCCS)
🇮🇹Candiolo, Torino, Italy
IRCCS - lstituto Nazionale Tumori - Fondazione G. Pascale
🇮🇹Napoli, Italy
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
Severance Hospital Yonsei University
🇰🇷Seoul, Korea, Republic of
National University Hospital
🇸🇬Kent Ridge, Singapore
National Cancer Center of Singapore
🇸🇬Singapore, Singapore
Instituto de Investigacion Oncologica Vall d'Hebron (VHIO) - EPON
🇪🇸Barcelona, Spain
NEXT Oncology-Hospital Quironsalud Barcelona
🇪🇸Barcelona, Spain
Hospital Universitario 12 de Octubre
🇪🇸Madrid, Spain
START MADRID_Hospital Universitario Fundacion Jimenez Diaz
🇪🇸Madrid, Spain
START MADRID_Hospital Universitario HM Sanchinarro - CIOCC
🇪🇸Madrid, Spain
Hospital Clinico Universitario de Valencia
🇪🇸Valencia, Spain
Sarah Cannon Research Institute UK
🇬🇧London, Middlesex, United Kingdom
Freeman Hospital
🇬🇧Newcastle Upon Tyne, Tyne And Wear, United Kingdom